610-22-0

Usage

Uses

Used in Pharmaceutical Industry:
Dimethyl 4-nitrophthalate is used as a key intermediate for the synthesis of N-α-hydroxyphthalimide, which is an important compound in the production of pharmaceuticals.
Used in Chemical Synthesis:
Dimethyl 4-nitrophthalate is used as a reagent in the synthesis of various chemical compounds, including dyes, pigments, and other organic compounds. Its versatility as an intermediate allows for the creation of a wide range of products in the chemical industry.

InChI:InChI=1/C10H9NO6/c1-16-9(12)7-4-3-6(11(14)15)5-8(7)10(13)17-2/h3-5H,1-2H3

Upstream product

• 67-56-1 methanol 
• 610-27-5 4-nitrophthalic acid 
• 75-75-2 methanesulfonic acid 
• 131-11-3 phthalic acid dimethyl ester 
• 24564-72-5 4-nitrophthalic acid chloride 

Downstream Products

• 5434-21-9 4-aminophthalic acid 
• 51832-31-6 4-amino-phthalic acid dimethyl ester 
• 437600-25-4 dimethyl 4-(2,2,2-trifluoroethoxy)phthalate 
• 437600-26-5 dimethyl 4-(2,2,3,3,4,4,4-heptafluorobutoxy)phthalate 
• 640295-93-8 4-{3-[(pyridine-2-carbonyl)-amino]-naphthalen-2-yloxy}-phthalic acid dimethyl ester 
• 640295-91-6 4-(3-benzoylamino-naphthalen-2-yloxy)-phthalic acid dimethyl ester 
• 640295-96-1 4-{3-[(4-chloro-pyridine-2-carbonyl)-amino]-naphthalen-2-yloxy}-phthalic acid dimethyl ester 
• 640295-98-3 4-{3-[(4-methyl-pyridine-2-carbonyl)-amino]-naphthalen-2-yloxy}-phthalic acid dimethyl ester 
• 640295-99-4 4-{3-[(4-ethyl-pyridine-2-carbonyl)-amino]-naphthalen-2-yloxy}-phthalic acid dimethyl ester 
• 640295-97-2 4-{3-[(4-methoxy-pyridine-2-carbonyl)-amino]-naphthalen-2-yloxy}-phthalic acid dimethyl ester 
• 640295-92-7 4-[3-(3-nitro-benzoylamino)-naphthalen-2-yloxy]-phthalic acid dimethyl ester 
• 640296-00-0 4-{3-[(4-trifluoromethyl-pyridine-2-carbonyl)-amino]-naphthalen-2-yloxy}-phthalic acid dimethyl ester 
• 22235-04-7 N-(1,3-dioxo-1,3-dihydroisobenzofuran-5-yl)-acetamide 
• 99-05-8 meta-aminobenzoic acid 

Relevant academic research and scientific papers

A High Selective Chemiluminescent Probe Derived from Iso-luminol Enabling High Sensitive Determination of Ferrous Ions in the Environmental Waters

A new chemiluminescence (CL) reagent named 4-amino-5-thiocyanato-phthalyl-hydrazine (iso-luminol-SCN) is synthesized by the bromide-mediated substitution reaction of iso-luminol with sodium thiocyanate in dimethyl formamide (DMF) at room temperature. Stro

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Unsymmetrically-Substituted 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-dione Scaffold—A Useful Tool for Bioactive Molecules Design

Unsymmetrically N-substituted and N,N’-disubstituted 5,12-dihydrodibenzo [b,f][1,4]diazocine-6,11-diones were synthesized in the new protocol. The desired modifications of the dibenzodiazocine scaffold were introduced at the stages of proper selection of building blocks as well as post-cyclization modifications with alkylation or acylation agents, expanding the structural diversity and possible applications of synthesized molecules. The extension of developed method resulted in the synthesis of novel: tricyclic 5,10-dihydrobenzo[b]thieno[3,4-f][1,4]diazocine-4,11-dione scaffold and fused pentacyclic framework possessing two benzodiazocine rings within its structure. Additionally, the unprecedented rearrangement of 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-diones to 2-(2-aminophenyl)isoindoline-1,3-diones was observed under the basic conditions in the presence of sodium hydride for secondary dilactams. The structures of nine synthesized products have been established by single-crystal X-ray diffraction analysis. Detailed crystallographic analysis of the investigated tri- and pentacyclic systems has shed more light on their structural features. One cell line derived from non-cancerous cells (EUFA30—human fibroblasts) and three tumor cells (U87—human primary glioblastoma, HeLa—cervix adenocarcinoma, BICR18—laryngeal squamous cell carcinoma) were used to determine the cytotoxic effect of the newly synthesized compounds. Although these compounds showed a relatively weak cytotoxic effect, the framework obtained for 5,12-dihydrodibenzo[b,f][1,4]diazocine-6,11-dione could serve as a convenient privilege structure for the design and development of novel bioactive molecules suitable for drug design, development and optimization programs.

HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10,Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

Stereoselective Synthesis of New (2 S,3 R)-3-Carboxyphenyl)pyrrolidine-2-carboxylic Acid Analogues Utilizing a C(sp3)-H Activation Strategy and Structure-Activity Relationship Studies at the Ionotropic Glutamate Receptors

Competitive antagonists for ionotropic glutamate receptors (iGluRs) are highly valuable tool compounds for studying health and disease states in the central nervous system. However, only few subtype selective tool compounds are available and the discovery of antagonists with novel iGluR subtype selectivity profiles remains a profound challenge. In this paper, we report an elaborate structure-activity relationship (SAR) study of the parental scaffold 2,3-trans-3-carboxy-3-phenyl-proline by the synthesis of 40 new analogues. Three synthetic strategies were employed with two new strategies of which one being a highly efficient and fully enantioselective strategy based on C(sp3)-H activation methodology. The SAR study led to the conclusion that selectivity for the NMDA receptors was a general trend when adding substituents in the 5′-position. Selective NMDA receptor antagonists were obtained with high potency (IC50 values as low as 200 nM) and 3-34-fold preference for GluN1/GluN2A over GluN1/GluN2B-D NMDA receptors.

Piperidinone carboxamide indane CGRP receptor antagonists

The present invention is directed to piperidinone carboxamide indane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Chemiluminescence properties of luminol related o-hydroxybenzimidazole analogues: Experimental and DFT based approach to photophysical properties

Novel luminol-isoluminol derivatives containing o-hydroxyphenyl benzimidazole unit were synthesized from aromatic aldehydes and diaminophthalates followed by heating under reflux with hydrazine hydrate. The chemiluminescent properties were studied in hydr

Chemiluminescence properties of luminol related quinoxaline analogs: Experimental and DFT based approach to photophysical properties

Novel luminol and isoluminol related compounds containing a quinoxaline moiety were synthesized by the reaction of various 1,2-diketones with dimethyl-4,5-diaminophthalate (5) and dimethyl-3,4-diaminophthalate (5′). The UV-Vis absorption and emission spectra of the dyes were studied in solvents of differing polarity and the compounds show solvatofluorism properties. The chemiluminescent properties of the isoluminol and luminol based quinoxaline derivatives were examined and compared with isoluminol and luminol. These compounds produced chemiluminescence by reaction with hydrogen peroxide in the presence of potassium hexacyanoferrate(III) in sodium hydroxide solution. The chemiluminescence intensities of these chemiluminophores were affected by the concentrations of hydrogen peroxide, potassium hexacyanoferrate(III) and sodium hydroxide. These quinoxaline derivatives were found to produce chemiluminescence in the range of 3.2-7.3 and it is 0.57-1.7 times more intensely than isoluminol and luminol, respectively. Density Functional Theory computations have been used for in-depth understanding of structural, molecular, electronic and photophysical parameters of the compounds.

PROCESS FOR MAKING CGRP RECEPTOR ANTAGONIST

The invention encompasses a novel process for making 2-[(8R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide, which is a CGRP receptor antagonist useful for the treatment of migraine, using an asymmetric phase-transfer catalysis route. The invention also encompasses an efficient and practical synthesis of the (R)-acid intermediate, and generates the benzylic stereocenter in an enantioselective manner.

PROCESS IMPROVEMENT USING SOLUBILITY CHARACTERISTICS

The present invention is directed to a process of maximizing the solubility of a nonelectrolyte solute in a solvent by operating within an optimal temperature range at conditions wherein the nonelectrolyte solute is not a pure liquid. In particular, the p